Azitra expands Phase 1/2 ATR-04 trial eligibility
Azitra adjusted the protocol of its topical ATR-04-484 Phase 1/2 study to include patients treating rash caused by KRAS and MEK inhibitors, widening the potential patient pool beyond those on EGFR inhibitors.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed